[go: up one dir, main page]

WO2003066881A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003066881A3
WO2003066881A3 PCT/US2003/003403 US0303403W WO03066881A3 WO 2003066881 A3 WO2003066881 A3 WO 2003066881A3 US 0303403 W US0303403 W US 0303403W WO 03066881 A3 WO03066881 A3 WO 03066881A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
methods
polypeptide
acids encoding
encoding same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/003403
Other languages
French (fr)
Other versions
WO2003066881A2 (en
Inventor
David W Anderson
Catherine E Burgess
Stacie J Casman
Linda Gorman
Weizhen Ji
Ramesh Kekuda
Li Li
Muralidhara Padigaru
Meera Patturajan
Carol E A Pena
Suresh G Shenoy
Richard A Shimkets
David J Stone
Raymond J Taupier Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/074,978 external-priority patent/US20040010119A1/en
Priority claimed from US10/138,588 external-priority patent/US20040018594A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to EP03710863A priority Critical patent/EP1513864A4/en
Priority to AU2003215010A priority patent/AU2003215010A1/en
Priority to CA002474652A priority patent/CA2474652A1/en
Priority to JP2003566229A priority patent/JP2005518200A/en
Publication of WO2003066881A2 publication Critical patent/WO2003066881A2/en
Anticipated expiration legal-status Critical
Publication of WO2003066881A3 publication Critical patent/WO2003066881A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2003/003403 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use Ceased WO2003066881A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03710863A EP1513864A4 (en) 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003215010A AU2003215010A1 (en) 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA002474652A CA2474652A1 (en) 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2003566229A JP2005518200A (en) 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding the same, and methods of use

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US35509902P 2002-02-08 2002-02-08
US60/355,099 2002-02-08
US35642402P 2002-02-12 2002-02-12
US10/074,978 2002-02-12
US60/356,424 2002-02-12
US10/074,978 US20040010119A1 (en) 2001-02-12 2002-02-12 Novel proteins and nucleic acids encoding same
US35792802P 2002-02-19 2002-02-19
US60/357,928 2002-02-19
US35860802P 2002-02-21 2002-02-21
US60/358,608 2002-02-21
US35986002P 2002-02-27 2002-02-27
US60/359,860 2002-02-27
US37557902P 2002-04-25 2002-04-25
US60/375,579 2002-04-25
US10/138,588 2002-05-01
US10/138,588 US20040018594A1 (en) 2001-05-03 2002-05-01 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US38166602P 2002-05-17 2002-05-17
US60/381,666 2002-05-17
US38700202P 2002-06-07 2002-06-07
US60/387,002 2002-06-07
US39326502P 2002-07-02 2002-07-02
US60/393,265 2002-07-02
US40182502P 2002-08-07 2002-08-07
US60/401,825 2002-08-07

Publications (2)

Publication Number Publication Date
WO2003066881A2 WO2003066881A2 (en) 2003-08-14
WO2003066881A3 true WO2003066881A3 (en) 2005-01-20

Family

ID=27739575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003403 Ceased WO2003066881A2 (en) 2002-02-08 2003-02-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (4)

Country Link
EP (1) EP1513864A4 (en)
JP (1) JP2005518200A (en)
AU (1) AU2003215010A1 (en)
WO (1) WO2003066881A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534353A1 (en) * 2003-08-01 2005-02-10 Zymogenetics, Inc. Adipocyte complement related protein zacrp11

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014241A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005374A2 (en) * 1998-07-22 2000-02-03 Incyte Pharmaceuticals, Inc. Molecules associated with cell proliferation
EP1222272A2 (en) * 1999-10-15 2002-07-17 Curagen Corporation Polypeptides and polynucleotides encoding same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014241A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN [online] 18 February 2000 (2000-02-18), HSIEH J.C. ET AL: "A new secreted protein that binds to Wnt proteins and inhibits their activities", XP002903254, accession no. NCBI Database accession no. (A59180) *
NATURE, vol. 398, no. 6726, 1999, pages 431 - 436 *
See also references of EP1513864A4 *

Also Published As

Publication number Publication date
EP1513864A4 (en) 2006-04-05
AU2003215010A1 (en) 2003-09-02
WO2003066881A2 (en) 2003-08-14
JP2005518200A (en) 2005-06-23
EP1513864A2 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002099116A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003085124A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002068647A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001025436A3 (en) Endozepine-like polypeptides and polynucleotides encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003215010

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2474652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003566229

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003710863

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003710863

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003710863

Country of ref document: EP